These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27481950)

  • 1. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.
    Toerner JG; Rubin D
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S37-8. PubMed ID: 27481951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
    Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
    Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Jul; 79(1):60-69. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
    Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
    Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
    Talbot GH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
    Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
    Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Kidd JM; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Talbot GH; Das A; Cush S; Dane A; Wible M; Echols R; Torres A; Cammarata S; Rex JH; Powers JH; Fleming T; Loutit J; Hoffmann S;
    J Infect Dis; 2019 Apr; 219(10):1536-1544. PubMed ID: 30649434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    Jones RN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Public-Private Collaborations Are Driving Solutions to the Antibacterial Drug Development Crisis.
    Madre L; Tenaerts P
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S25-6. PubMed ID: 27481948
    [No Abstract]   [Full Text] [Related]  

  • 18. Consensus on Language for Advance Informed Consent in Health Care-Associated Pneumonia Clinical Trials Using a Delphi Process.
    Corneli A; Calvert SB; Powers JH; Swezey T; Collyar D; Perry B; Farley JJ; Santiago J; Donnelly HK; De Anda C; Blanchard K; Fowler VG; Holland TL
    JAMA Netw Open; 2020 May; 3(5):e205435. PubMed ID: 32442291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumonia.
    Puzniak L; Dillon R; Lodise T
    PLoS One; 2023; 18(1):e0279844. PubMed ID: 36598902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.